

Stem Cell Reports, Volume 9

Supplemental Information

**Efficient Large-Scale 2D Culture System for Human Induced Pluripotent
Stem Cells and Differentiated Cardiomyocytes**

Shugo Tohyama, Jun Fujita, Chihana Fujita, Miho Yamaguchi, Sayaka Kanaami, Rei Ohno, Kazuho Sakamoto, Masami Kodama, Junko Kurokawa, Hideaki Kanazawa, Tomohisa Seki, Yoshikazu Kishino, Marina Okada, Kazuaki Nakajima, Sho Tanosaki, Shota Someya, Akinori Hirano, Shinji Kawaguchi, Eiji Kobayashi, and Keiichi Fukuda

Figure S1








Figure S2



1
2
3
4
5

Figure S3



1
2
3

1 **SUPPLEMENTAL FIGURE LEGENDS**

2 **Figure S1. hiPSCs were cultured in a four-layer CP under AGV, related to Figure 1.**

3 (A) The scheme of cell culture in a four-layer CP under AGV. The total volume of medium
4 was 500 mL/CP. (B) Growth curve of hiPSCs (253G4) in a four-layer CP. Each dot
5 represents a passage of cells. (C) The proliferation rate in a four-layer CP (n = 8) under AGV
6 was as much as that in a single layer CP (n = 17). Each bar represents the fold changes from
7 individual passages. (D) Immunofluorescent staining showed that hiPSCs expressed the
8 pluripotent markers NANOG, OCT4, TRA1-60, and SSEA4. Bars are 100 μ m. (E) pCO₂,
9 pO₂, pH, and the concentrations of glucose and glutamine during cultivation in a four-layer
10 CP under NGV or AGV (n = 3 independent experiments). Data are presented as means \pm SD.
11 **p* < 0.05

12

13 **Figure S2. The AGV system was more efficient for gas exchange than NGV in a 10-layer**
14 **CP, related to Figure 2.**

15 (A and B) Oxygen concentration was measured in the fifth layer of the 10-layer CP under
16 AGV (A) and NGV (B). (C) FACS analyses of pluripotent markers in hiPSCs cultured using
17 10-layer CPs under AGV. (D) pCO₂, pO₂, and pH levels during cultivation in a 10-cm culture
18 dish under NGV (n = 3 independent experiments).

19

20 **Figure S3. Large-scale culture of cardiac differentiation from hiPSCs in a multilayer**
21 **CP, related to Figure 3.**

22 (A) A pellet of the hiPSC (253G4)-derived cells cultured using one four-layer CP under AGV.
23 (B) Total cell number of hiPSC-derived cells in four-layer CPs under AGV (253G4; n = 8,
24 201B7; n = 4, Ffl14; n = 5). Data were obtained from independent experiments. (C) Total
25 cell numbers and cardiomyocyte (CM) numbers of hiPSC (Ffl14)-derived cells in 10-layer

1 CPs under NGV or AGV (n = 4 independent experiments). **(D)** Color of medium in hiPSC-
2 derived cells cultured using 10-layer CPs under NGV (left) or AGV (right). **(E)**
3 Representative immunofluorescence staining for α -actinin (green) and nuclei (blue) in hiPSC
4 (Ffi14)-derived dispersed cells after metabolic selection. **(F)** Representative FACS analysis
5 for troponin T-positive cells in hiPSC (Ffi14)-derived cells before (left) and after (right)
6 metabolic selection. **(G)** The proportion of troponin T-positive CMs in hiPSC (Ffi14)-derived
7 dispersed cells after metabolic selection (n = 6 independent experiments). **(H)** Yield-based
8 efficiencies by metabolic selection (n = 5 independent experiments). **(I)** The bar graphs show
9 viability of cryopreserved hiPSC-derived pure cardiomyocytes after thawing (253G4; n = 5,
10 Ffi14; n = 6). Data were obtained from independent experiments. Scale bars represent 500
11 μm **(E)**. Data are presented as means \pm SD.

12

13 **Movie S1. Purified hiPSC-derived dispersed CMs, related to Figure 3.**

14 After differentiation using four-layer CPs, hiPSC (253G4)-derived cells were dissociated and
15 seeded on fibronectin-coated single-layer CPs. Then, the cells were metabolically selected
16 under glucose- and glutamine-depleted conditions in the presence of lactate and reseeded.

17

1 **SUPPLEMENTAL EXPERIMENTAL PROCEDURES**

2 **Maintenance of hiPSCs using single- or multilayer CPs**

3 The hiPSC lines (253G4, 201B7, and Ffi14) were obtained from the Center for iPSC
4 Research and Application, Kyoto University. hiPSCs were maintained in modified Stem Fit
5 Medium (Ajinomoto Co., Inc., Japan) on growth factor-reduced Matrigel-coated single- or
6 multilayer (four- or 10-layer) CPs (Thermo Fisher Scientific, USA). In the active gas
7 ventilation (AGV) system, 50 mL/min 5% CO₂ per layer was actively ventilated using a
8 multi-gas incubator (MG-70M; TAITEC Corporation, Japan). hiPSCs were routinely
9 passaged every week using Accutase (Thermo Scientific). Briefly, cells were washed with D-
10 PBS and incubated with Accutase at 37°C. After incubation, cells were collected and
11 reseeded in modified Stem Fit Medium (Ajinomoto) with 10 μM Y27632 (Wako Pure
12 Chemicals, Japan) on growth factor-reduced Matrigel-coated (BD Biosciences, Japan) culture
13 plates. Media were changed every other day (Nakagawa et al., 2014). The number of
14 dissociated single cells was counted using a Vi-Cell cell counter (Beckman Coulter, USA).
15 Karyotypes of hiPSCs were analyzed by Nihon Gene Research Laboratories, Inc. (Sendai,
16 Japan, <http://www.ngrljapan.com>).

17

18 **2D cardiomyocyte differentiation using multilayer CPs with NGV or AGV**

19 hiPSCs (1.5×10^7 cells/layer) were seeded in modified Stem Fit Medium (Ajinomoto) on
20 Matrigel-coated multilayer CPs (4 or 10 layers) with NGV or AGV on day -4. When the cells
21 reached 90% confluence on day 0, the medium was changed to RPMI (Wako) with B27
22 minus insulin (Thermo Scientific), 6 μM CHIR99021 (Wako), and 1 ng/mL bone
23 morphogenic protein 4 (R&D Systems) from day 0 to day 1, as previously reported (Lian et
24 al., 2012; Tohyama et al., 2016), with modifications. The medium was changed to RPMI with
25 B27 minus insulin on day 1. On day 3, the medium was changed to RPMI with B27 minus

1 insulin and 5 μ M IWR1 (Sigma-Aldrich, USA). On day 6, the medium was changed to RPMI
2 with B27 minus insulin. Cells were maintained in MEM α plus 5% fetal bovine serum (FBS;
3 Hyclone) on day 7. From day 7 onwards, the medium was changed every 3–7 days. At day 10
4 after differentiation, the number of dissociated single cells and cell viability were evaluated
5 by trypan blue staining using a ViCell (Beckman Coulter). Differentiation efficiencies were
6 analyzed using fluorescence-assisted cell sorting (FACS) analysis (Gallios; Beckman
7 Coulter).

8

9 **Purification of hiPSC-CMs by metabolic selection system**

10 On differentiation days 12–14, hiPSC-derived cells were incubated with D-PBS to remove
11 RPMI with B27 plus insulin for 3 min and then enzymatically dissociated using 0.25%
12 Trypsin-EDTA (Nacalai Tesque). Dissociated cells were collected and seeded on collagen
13 type 1- (IWAKI, Japan) or fibronectin-coated (Sigma) 15 cm dishes or fibronectin-coated
14 single-layer CPs (Thermo Scientific) using MEM α plus 5% FBS. After 1-2 days of
15 cultivation using MEM α plus 5% FBS, hiPSC-derived cells were incubated with D-PBS to
16 remove MEM α plus 5% FBS for 3 min, and the medium was then changed to glucose and
17 glutamine-free DMEM (Ajinomoto) supplemented with 4 mM L-lactic acid and 0.1% BSA
18 (Thermo Scientific) for 3–6 days, as reported previously (Tohyama et al., 2016). The medium
19 was changed every 2 or 3 days to eliminate dead cells. After metabolic selection, purified
20 hiPSC-CMs were cryopreserved or used for immunostaining and FACS analysis.

21

22 **Components of modified StemFit**

23 In this study, we used modified StemFit medium manufactured by Ajinomoto Co., Inc. As
24 well as StemFit medium (Nakagawa et al., 2014), modified StemFit medium containing 21
25 amino acids (L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cyctine, L-

1 glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-
2 methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-
3 valine), 10 vitamins (L-ascorbic acid, cobalamin, biotin, folic acid, I-inositol, niacinamide, D-
4 calcium pantothenate, pyridoxine hydrochloride, riboflavin, and thiamine hydrochloride),
5 five trace minerals (cupric sulfate, ferric sulfate, ferric nitrate, zinc sulfate, and sodium
6 selenite), and growth factors, including basic fibroblast growth factor. Compared with
7 StemFit medium, the quantities of most ingredients were increased for large-scale culture.

8

9 **Alkaline phosphatase staining**

10 Alkaline phosphatase staining was performed using a Leukocyte Alkaline Phosphatase kit
11 (Sigma) as described previously (Tohyama et al., 2016).

12

13 **Visualization of gas exchange in a multilayered CP under AGV**

14 A 10-layered culture plate (TAITEC) was filled with 2 L PBS with 20 mg phenol red, and 50
15 mL/min 5% CO₂ per layer was actively ventilated. A photograph was taken every 10 min.

16

17 **Measurement of gas exchange rate**

18 In order to measure the gas exchange rate in the AVG system, 500 mL/min N₂ was actively
19 ventilated using the MG-70M multi-gas incubator (TAITEC) through the 10-layered CP. In
20 the NGV system, the 10-layer CP was placed under hypoxic conditions (1% O₂). A sensor tip
21 (SP-PSt3-YAU-D5; PreSens, Germany) and optical fiber (POF-1MSA; PreSens, Germany)
22 were placed in the fifth layer of the 10-layer CP. The oxygen concentration was measured
23 using Fibox 3 (PreSens, Germany).

24

25 **Immunocytochemistry**

1 Cells were fixed with 4% paraformaldehyde for 20 min. Subsequently, cells were
2 permeabilized with 0.1% Triton X-100 (Sigma) at room temperature for 5 min and then
3 incubated with primary antibodies, i.e., 1:500 dilution of mouse anti- α -actinin (Sigma,
4 A7811), 1:200 dilution of mouse anti-cardiac troponin T (Thermo Scientific, MS-295-p),
5 1:200 dilution of mouse anti-MLC2a (Synaptic System, Germany, 311011), 1:200 dilution of
6 rabbit anti-MLC2v (ProteinTech, USA, 10906-1-AP), 1:200 dilution of rabbit anti-NANOG
7 (ReproCELL, Japan, RCAB003P), 1:200 dilution of mouse anti-OCT4 (Santa Cruz
8 Biotechnology, USA, sc-5279), 1:200 dilution of anti-TRA1-60 (Millipore, Germany,
9 MAB4360), 1:200 dilution of mouse anti-TRA1-81 (Millipore, MAB4381), and 1:200
10 dilution of mouse anti-SSEA4 (Millipore, MAB4304), overnight at 4°C. Cells were then
11 washed with PBS containing 0.1% Tween 20 three times prior to incubation with secondary
12 antibodies (Alexa Fluor 488/594 anti-mouse IgG or IgM and Alexa Fluor 488/594 anti-rabbit
13 IgG) for 1 h at room temperature. After nuclear staining with Hoechst 33342 (Thermo
14 Scientific), stained cells were detected by fluorescence microscopy (Axio Observer; Carl
15 Zeiss, Jena, Germany).

16

17 **FACS analysis**

18 hiPSCs or differentiated CMs were completely dissociated using 0.25% trypsin-
19 ethylenediaminetetraacetic acid (EDTA) and then fixed with 4% paraformaldehyde for 20
20 min. Subsequently, cells were permeabilized with 0.1% Triton X-100 (Sigma) at room
21 temperature for 5 min and incubated with primary antibodies, i.e., 1:200 dilution of mouse
22 anti-OCT4 (Santa Cruz Biotechnology, sc-5279), 1:200 dilution of mouse anti-TRA1-60
23 (Millipore, MAB4360), 1:200 dilution of mouse anti-SSEA4 (Millipore, MAB4304), and
24 1:200 dilution of mouse anti-cardiac troponin T (Thermo Scientific, MS-295-p), at 4°C
25 overnight. Cells were washed with PBS containing 0.1% Tween 20 prior to incubation with

1 Alexa 488 donkey anti-mouse IgG secondary antibodies (Thermo Scientific) at room
2 temperature for 2 h. Cells were analyzed by FACS. Negative controls used for gating were
3 based on the cells stained with isotype control antibodies.

4

5 **Cryopreservation of purified hiPSC-CMs**

6 After purification, the cells were isolated using 0.25% trypsin-EDTA for 10 min at 37°C. The
7 isolated cells were counted using a ViCell (Beckman Coulter) and cryopreserved in STEM-
8 CELLBANKER (Nippon Zenyaku Kogyo Co., Ltd., Japan) using BICELL (Nihon Freezer,
9 Japan). After thawing the hiPSC (253G4 and Ffl14)-CMs, cell viabilities were evaluated by
10 trypan blue staining using a Vi-Cell cell counter (Beckman Coulter).

11

12 **Action potential recordings**

13 After thawing the hiPSC (253G4)-CMs, cells were seeded on fibronectin-coated (Sigma)
14 probes. Then, action potentials were recorded as previously described (Hemmi et al., 2014;
15 López-Redondo et al., 2016). Current-clamp recording was conducted in normal Tyrode's
16 solution containing 135 mM NaCl, 0.33 mM NaH₂PO₄, 5.4 mM KCl, 1.8 mM CaCl₂, 0.53
17 mM MgCl₂, 5.5 mM glucose, and 5 mM HEPES (pH 7.4 at 35°C) using the pipette solution:
18 60 mM KOH, 80 mM KCL, 40 mM aspartate, 5 mM HEPES, 10 mM EGTA, 5 mM Mg ATP,
19 5 mM sodium creatinine phosphate, and 0.65 mM CaCl₂ (pH 7.2 adjusted with KOH).
20 Amphotericin B was added to the pipette solution (final concentration 0.3 g/L) to perforate
21 the cell membrane just before use.

22

23 **Field potential recordings using a multi-electrode array system**

24 To characterize the functional properties of our purified hiPSC (253G4)-derived CMs, we
25 performed extracellular recording of field potentials (FPs) using a multi-electrode array

1 (MEA) system (MED 64; AlphaMED Scientific, Japan), as described previously (Egashira et
2 al., 2012; Nakamura et al., 2014; Tanaka et al., 2009). After thawing of hiPSC-derived CMs,
3 cells were seeded on fibronectin-coated (Sigma) probes. The recorded extracellular
4 electrograms were used to determine field potential duration (FPD), defined as the time
5 interval between the initial deflection of the FP and the maximum T wave. FPD
6 measurements were corrected by Bazett's correction formulae (corrected FPD = FPD / [RR
7 interval]^{1/2}), where RR indicates the time interval (s) between two consecutive beats. The
8 temperature was maintained at 37°C during these recordings. After incubation for 10–15 min
9 with E4031 (a gift from Esai, Japan) or (-)-isoproterenol hydrochloride (Sigma), the FPs were
10 measured. In experiments using E4031, different channels were analyzed in the MEA probe.
11 In experiments using isoproterenol, different probes were analyzed. The temperature was
12 maintained at 37°C during these recordings.

13

14 **Statistics**

15 Values are presented as means ± SD or SEM. Statistical significance was evaluated using
16 Student's t tests for comparisons between two mean values. Multiple comparisons between
17 more than three groups were performed using analysis of variance with Dunnett's multiple
18 comparison tests. Results with *p* values of less than 0.05 were considered significant.

19

20

21

22

23

24

25

1 **References**

- 2 Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsushashi, T., Ohno, Y.,
3 Tohyama, S., Okata, S., Seki, T., *et al.* (2012). Disease characterization using LQTS-specific
4 induced pluripotent stem cells. *Cardiovasc Res* *95*, 419-429.
- 5 Hemmi, N., Tohyama, S., Nakajima, K., Kanazawa, H., Suzuki, T., Hattori, F., Seki, T.,
6 Kishino, Y., Hirano, A., Okada, M., *et al.* (2014). A Massive Suspension Culture System
7 With Metabolic Purification for Human Pluripotent Stem Cell-Derived Cardiomyocytes.
8 *Stem Cells Translational Medicine* *3*, 1473-1483.
- 9 Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., Zhang,
10 J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human
11 pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad*
12 *Sci U S A* *109*, E1848-1857.
- 13 López-Redondo, F., Kurokawa, J., Nomura, F., Kaneko, T., Hamada, T., Furukawa, T., and
14 Yasuda, K. (2016). A distribution analysis of action potential parameters obtained from
15 patch-clamped human stem cell-derived cardiomyocytes. *Journal of Pharmacological*
16 *Sciences* *131*, 141-145.
- 17 Nakagawa, M., Taniguchi, Y., Senda, S., Takizawa, N., Ichisaka, T., Asano, K., Morizane, A.,
18 Doi, D., Takahashi, J., Nishizawa, M., *et al.* (2014). A novel efficient feeder-free culture
19 system for the derivation of human induced pluripotent stem cells. *Sci Rep* *4*, 3594.
- 20 Nakamura, Y., Matsuo, J., Miyamoto, N., Ojima, A., Ando, K., Kanda, Y., Sawada, K.,
21 Sugiyama, A., and Sekino, Y. (2014). Assessment of Testing Methods for Drug-Induced
22 Repolarization Delay and Arrhythmias in an iPS Cell–Derived Cardiomyocyte Sheet: Multi-
23 site Validation Study. *Journal of Pharmacological Sciences* *124*, 494-501.
- 24 Tanaka, T., Tohyama, S., Murata, M., Nomura, F., Kaneko, T., Chen, H., Hattori, F.,
25 Egashira, T., Seki, T., Ohno, Y., *et al.* (2009). In vitro pharmacologic testing using human

1 induced pluripotent stem cell-derived cardiomyocytes. *Biochem Biophys Res Commun* 385,
2 497-502.

3 Tohyama, S., Fujita, J., Hishiki, T., Matsuura, T., Hattori, F., Ohno, R., Kanazawa, H., Seki,
4 T., Nakajima, K., Kishino, Y., *et al.* (2016). Glutamine Oxidation Is Indispensable for
5 Survival of Human Pluripotent Stem Cells. *Cell Metab* 23, 663-674.

6